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Androgen insensitivity syndrome
Ieuan A Hughes, John D Davies, Trevor I Bunch, Vickie Pasterski, Kiki Mastroyannopoulou, Jane MacDougall
Androgen insensitivity syndrome in its complete form is a disorder of hormone resistance characterised by a female 
phenotype in an individual with an XY karyotype and testes producing age-appropriate normal concen trations of 
androgens. Pathogenesis is the result of mutations in the X-linked androgen receptor gene, which encodes for the 
ligand-activated androgen receptor—a transcription factor and member of the nuclear receptor superfamily. This 
Seminar describes the clinical manifestations of androgen insensitivity syndrome from infancy to adulthood, reviews 
the mechanism of androgen action, and shows examples of how mutations of the androgen receptor gene cause the 
syndrome. Management of androgen insensitivity syndrome should be undertaken by a multidisciplinary team and 
include gonadectomy to avoid gonad tumours in later life, appropriate sex-hormone replacement at puberty and 
beyond, and an emphasis on openness in disclosure.
Introduction
Several clinical disorders arise because of complete 
or partial resistance to the action of hormones.1 
Examples include diabetes due to insulin resistance2 
and reproductive disorders caused by resistance to 
gonadotropin and steroid hormones.3 Male development 
during fetal life occurs only when an XY zygote directs 
the bipotential gonad to become a testis (sex deter-
mination), which in turn secretes suﬃ  cient amounts of 
active androgen to produce the male phenotype (sex 
diﬀ erentiation).4 Figure 1 shows the pathway of healthy 
male and female fetal sex development, modiﬁ ed to 
include complete resistance to the action of androgens 
resulting in a female phenotype—ie, a hormone-
resistance syndrome.
Hormone-resistance syndrome was fully characterised 
by John Morris, who reviewed the clinical features of 
82 patients.5 Because the patients were women and girls 
with bilateral testes that seemed to produce oestrogen-like 
hormones, Morris coined the term testicular feminisation 
syndrome. This contradictory label was renamed as 
complete androgen insensitivity syndrome, which is now 
the accepted terminology.6 Partial androgen insensitivity 
syndrome refers to a phenotype of varying degrees of 
masculinisation of the external genitalia due to partial 
androgen responsiveness. Mild androgen insensitivity 
syndrome is reported in healthy men and boys who can 
present with adolescent gynaecomastia or infertility in 
later life. Thus, androgen insensitivity syndrome can be 
deﬁ ned as a disorder resulting from complete or partial 
resistance to the biological actions of androgens in an XY 
man or boy with normal testis determination and 
production of age-appropriate androgen concentrations. 
The pathophysi ology of this syndrome is based on the 
mechanism of action of androgens (appendix).
Complete androgen insensitivity syndrome
Clinical presentation
The typical presentation for complete androgen insensi-
tivity syndrome is either primary amenorrhoea in 
adolescence, or inguinal swellings in an infant. A female 
adolescent with the disorder has breast development and 
a pubertal growth spurt at the appropriate age, but no 
menses. Development of oestrogen-dependent secondary 
sexual characteristics occurs as the result of excess 
aromatisation of androgens. Pubic and axillary hair is 
usually absent or can be present in sparse amounts. No 
precise ﬁ gures are available for the prevalence of 
complete androgen insensitivity syn drome, but estimates 
range from one in 20 400 to one in 99 100 genetic males 
on the basis of a proven molecular diagnosis.7
In infancy, complete androgen insensitivity syndrome 
presents as an inguinal hernia or labial swelling containing 
a testis in an apparently female infant. Bilateral inguinal 
herniae are rare in female infants—the incidence of 
complete androgen insensitivity syndrome in such 
patients is 1–2% during infancy.8,9 Clinicians recommend 
that karyotyping or a biopsy of a gonad within the hernial 
sac is done after the parents give consent.10 Alternatively, 
vaginal length can be measured in prepubertal girls 
undergoing inguinal hernia repair to screen for complete 
androgen in sensitivity syndrome;9 a shortened vagina and 
the absence of ovaries or fallopian tubes suggests the need 
for karyotyping. The uterus, cervix, and proximal vagina 
are absent in complete androgen insensitivity syndrome 
because of the action of antimüllerian hormone produced 
by Sertoli cells of the testis.4 The vagina varies from a 
dimple in the perineum to normal length, but is always 
blind-ending. Occasionally, older sisters of people with 
complete androgen insensitivity syndrome have also had 
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Search strategy and selection criteria
We searched PubMed mainly with the search terms 
“androgen insensitivity syndrome” in combination with the 
additional terms “complete” and “partial”. For the molecular 
section, we searched for the terms “androgen receptor”, 
“androgen receptor mutation”, “nuclear receptor”, and 
“nuclear receptor co-regulators”. For the management 
section, we used the terms “germ cell tumours”, “hormone 
replacement therapy”, “vaginal dilators”, and “gender 
identity”. We selected publications from the past 10 years, but 
older papers related to ﬁ rst descriptions of the syndrome are 
cited, as are relevant review articles from monographs and 
book chapters.
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an inguinal hernia repair in infancy, and can have a 46,XY 
karyotype (unpublished).
Diagnosis of complete androgen insensitivity syn-
drome can happen by chance. The sex of a fetus is now 
increasingly known before birth through analysis of 
karyotypes, chorionic villi, amniotic ﬂ uid samples, or 
maternal circulating free fetal DNA,11 and use of three-
dimensional ultrasonography. Complete androgen 
insen sitivity syndrome can therefore some times be diag-
nosed as a result of mismatch between the prenatal sex 
prediction and the phenotype at birth.12 Other modes of 
presentation include a known family history of X-linked 
complete androgen insensitivity syndrome and, 
occasion ally, the discovery of a pelvic mass arising from 
a gonadal tumour.13
Adult women with complete androgen insensitivity 
syndrome are generally taller than women without 
the syndrome, but are on average shorter than the male 
population.14 Patients in whom gonadectomy is delayed 
are even taller, suggesting a relative oestrogen deﬁ ciency 
before gonadectomy.15 However, no evidence shows that 
girls with complete androgen insensitivity syndrome start 
puberty later than girls without the syndrome.16 The 
enlarged adult stature in the syndrome is mainly due to 
the eﬀ ect of the growth-controlling region on the long 
arm of the Y chromosome, but genome-wide association 
studies have identiﬁ ed several loci that aﬀ ect adult 
height.17 Infants with complete androgen insensitivity 
syndrome are on average the same size at birth as male 
infants, suggesting that factors on the Y chromosome 
rather than exposure to prenatal androgens explain the 
sex dimorphism.18
Endocrine features
Women with complete androgen insensitivity syndrome 
who have intact gonads have the endocrine proﬁ le of 
a hormone-resistant state. Serum testosterone concen-
trations are either within or above the normal range 
for men and boys and luteinising hormone (LH) 
concen trations are inappropriately increased.19 Con cen-
trations of follicle-stimulating hormone and inhibin are 
gener ally normal. Excess testosterone is produced and 
peripherally aromatised to oestrogen which, together 
with LH-induced direct secretion of testicular oestrogen, 
results in serum oestradiol concentrations higher than 
those noted in men and boys but lower than those 
reported in women without complete androgen insensi-
tivity syndrome.20 Serum gonadotropin concentrations 
increase further after gonadectomy, but are only 
partly suppressed with oestrogen substitution. These 
ﬁ ndings suggest resistance to the negative-feedback 
eﬀ ect of androgens on hypothalamic–pituitary control 
of gonadotropin secretion in complete androgen in-
sensitivity syndrome, but maintenance of a partial 
negative feedback by oestrogens. Concentrations of sex-
hormone-binding globulin are sexually dimorphic; 
androgens decrease and oestrogens increase hepatic 
production, respectively. Concentrations of this protein 
in patients with complete androgen insensitivity 
syndrome are similar to those in women without 
the syndrome and do not decrease after androgen 
administration.21
The pattern of gonadotropin and testosterone con-
centrations is less suggestive of hormone resistance 
when complete androgen insensitivity syndrome pre-
sents in infancy.22,23 Usually, LH-induced serum testos-
terone concentrations surge during the ﬁ rst few months 
of life—a so-called mini-puberty.24,25 This proﬁ le, however, 
cannot be used to diagnose complete androgen in-
sensitivity syndrome in many infants, although serum 
testosterone concentrations do increase appropriately 
after stimulation with human chorionic gonadotropin.22 
Infants with partial androgen insensitivity syndrome 
have a more responsive pattern of LH and testosterone, 
both basally and after stimulation with human chorionic 
gonadotropin. The human chorionic gonadotropin 
stimulation test is key to exclusion of other causes that 
give rise to a similar phenotype.
Low testosterone concentrations in infants with 
complete androgen insensitivity syndrome are not fully 
understood but might suggest that androgens need to act 
prenatally on the hypothalamic–pituitary axis to prime 
the LH surge after birth. Serum antimüllerian hormone 
concentrations also rise in the neonatal period and are 
sexually dimorphic.24,26,27 Serum antimüllerian hormone 
measurement not only suggests the presence of testes in 
complete androgen insensitivity syndrome, but also that 
concentrations are higher in infants with the syndrome 
than in male infants.28 Concentrations of testosterone 
and antimüllerian hormone are inversely associated 
during male puberty, but this relation does not hold 
during the so-called mini-puberty of infancy. This 
discrepancy occurs because androgen receptors are not 
expressed in Sertoli cells of the infant testis, suggesting a 
state of transient androgen insensitivity in Sertoli cells 
Zygote at fertilisation
Bipotential gonad
XY
Testis
XX
Ovary
AMH
No müllerian ducts
Androgens/ARWolﬃan ducts;
male genitalia
Male phenotype
No AMH
Müllerian ducts
No androgens No wolﬃan ducts;
female genitalia
Female phenotype
CAIS
No AR
Figure 1: Simpliﬁ ed pathway of fetal sex development
AR=androgen receptor. CAIS=complete androgen insensitivity syndrome. AMH=antimüllerian hormone.
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during the fetal and neonatal stages of testis develop-
ment.29 This insensitivity is ampliﬁ ed in complete 
androgen insensitivity syndrome, resulting in even 
higher concen trations of antimüllerian hormone, which 
distinguishes the syndrome from complete gonadal 
dysgenesis, a disorder of impaired Sertoli cell function.
The diﬀ erential diagnosis for complete androgen 
insensitivity syndrome in female adolescents includes 
other causes of primary amenorrhoea such as complete 
gonadal dysgenesis,30 Mayer-Rokitansky-Kuster-Hauser 
syndrome, and other müllerian duct anomalies— 
eg, transverse vaginal septae. Other diﬀ erential diagnoses 
include various androgen biosynthesis disorders 
(appendix).31
Partial androgen insensitivity syndrome
The clinical presentation of partial androgen insensitivity 
syndrome depends on the degree of responsiveness of 
the external genitalia to androgens. The typical pheno-
type is micropenis, severe hypospadias (perineo scrotal), 
and a biﬁ d scrotum that might contain gonads. 
Occasionally, the appearance of the genitalia is more 
consistent with complete androgen insensitivity 
syndrome, apart from the degree of clitoromegaly. This 
presentation is referred to as severe partial androgen 
insensitivity syndrome, and sex assignment is generally 
female. Panel 1 lists the causes of undermasculinised 
men and boys with pheno types similar to that of partial 
androgen insensitivity syndrome. Extensive genetic and 
biochemical investi gations are needed to conﬁ rm 
diagnosis. Workers have reported guidance on how to 
investigate partial androgen insen sitivity syndrome and 
other disorders of sex development presenting at birth 
or in adolescence.32 Hypospadias is a common male 
congenital malformation (prevalence up to eight cases 
per 1000 births) that is often associated with low 
birthweight of unknown cause.33 Sequencing of the 
androgen receptor gene to identify an abnormal receptor 
is needed for a ﬁ rm diagnosis of partial androgen 
insensitivity syndrome. If possible, an in-vitro functional 
assay should be done to conﬁ rm pathogenicity.
Mild androgen insensitivity syndrome
Mild androgen insensitivity syndrome is associated with 
a mutation of the androgen receptor gene and is 
infrequently reported. It presents in men as infertility 
but is not associated with genital anomalies.34 Fertility is 
possible if the sperm count can be restored after high-
dose androgen treatment.35 The product of serum LH 
and testosterone concentrations as an index of possible 
mild androgen insensitivity syndrome in infertile men 
could be a useful screening test for the presence of a 
mutation in the androgen receptor gene. The results of 
conditional knockout experiments of the androgen 
receptor in mice show that a functional receptor 
expressed in Sertoli and Leydig cells is essential for 
normal spermatogenesis.36
Mild androgen insuﬃ  ciency syndrome can also mani-
fest as bulbar and spinal muscular atrophy (Kennedy’s 
disease).37 In addition to the characteristic weakness and 
wasting of bulbar, facial, and limb muscles, patients with 
this neurological disorder have increased testosterone 
concentrations that are associated with gynaecomastia and 
reduced fertility, which is consistent with mild androgen 
insensitivity. The pathogenesis of bulbar and spinal 
muscular atrophy is associated with hyperexpansion of the 
CAG repeat (more than 38) in exon 1 of the androgen 
receptor gene, leading to a toxic gain of function.38 
Experiments in which transgenic mice with hyperexpanded 
CAG repeats were crossed with mice with inactive 
androgen receptors showed increased deleterious neuro-
muscular and endocrine–reproductive features.39 Variation 
in the number of CAG repeats within the normal ranges is 
associated with several androgen-related disorders such as 
polycystic ovary syndrome, male infertility, male pattern 
baldness, metabolic syndrome, and prostate cancer, and 
even with growth during childhood in boys.40 Such 
associations alone are unlikely to have much clinical 
relevance, but the number of CAG repeats can have 
modulatory eﬀ ects on the phenotypic manifestation of 
some mutations of the androgen receptor gene noted in 
partial androgen insensitivity syndrome, particularly when 
the phenotype varies with the same mutation.41
Molecular pathogenesis
In complete and partial androgen insensitivity 
syndrome, mis-sense mutations are distributed 
throughout the eight exons of the androgen receptor 
gene, but localised mainly in exons that encode the 
Panel 1: Causes of a PAIS-like phenotype
Defects in androgen production
• Partial gonadal dysgenesis
• Mutations in SRY, NR5A1, WT1
• Mutations of the luteinising hormone receptor
• Biosynthetic enzyme deﬁ ciencies
• 17,20-lyase deﬁ ciency
• P450 oxidoreductase deﬁ ciency
• 17β-hydroxysteroid dehydrogenase deﬁ ciency type 3
• 5α-reductase deﬁ ciency type 2
Genetic
• Klinefelter’s syndrome
• Smith-Lemli-Opitz syndrome
• Denys-Drash syndrome
• Frasier’s syndrome
PAIS
• Mutations of the androgen receptor gene
• Normal androgen receptor gene with fetal growth 
restriction
PAIS=partial androgen insensitivity syndrome. SRY=sex-determining region Y. 
NR5A1=nuclear receptor subfamily 5 A1. WT1=Wilms’ tumour 1. 
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DNA-binding and ligand-binding domains where their 
functional eﬀ ect is great because of the ordered structure 
of these domains (appendix).42
Genital skin ﬁ broblasts express androgen receptors in 
high concentrations and can be used to measure 
androgen binding when a skin biopsy is taken at 
surgery.43 Typically, binding is absent in complete 
androgen insensitivity syndrome and binding aﬃ  nity 
(Kd) is altered in partial and mild androgen insensitivity 
syndrome. Genital skin ﬁ broblasts can be used to identify 
genomic mutations that disrupt normal RNA splicing, 
quantify androgen receptor expression by western blots, 
and study the phenotypic variance recorded between 
patients with the same mutation.44,45
Automated DNA sequencing of the coding region and 
splice sites of the androgen receptor gene is now 
routinely available in the UK. A mutation is identiﬁ ed in 
more than 95% of patients with complete androgen 
insensitivity syndrome. The transcriptional activity of 
new mutant androgen receptors might need to be 
assessed, especially in patients with a phenotype for 
partial or mild disease. Information from functional 
assays has clinical relevance with regard to hormone 
treatment for patients with androgen insensitivity 
syndrome who were raised male.46,47 Androgen receptor 
function and mutations correlate somewhat in utero; this 
association is shown by the degree of external genital 
masculinisation.48 Transcriptional activity is generally 
absent or severely impaired on a physiological andro-
gen basis in studies of androgen-receptor mutations 
associated with a phenotype of complete androgen 
insensitivity syndrome. The spontaneous mutation rate 
in complete androgen insensitivity syndrome is about 
30%—a ﬁ nding consistent with other X-linked recessive 
disorders such as haemophilia (due to factor VIII 
deﬁ ciency) and Duchenne muscular dystrophy.49 Most 
de-novo mutations are postzygotic and somatic mosai-
cism for the mutant androgen receptor can occur.50 
Phenotypic variation for the same mutation can occur 
and is noted within aﬀ ected families.51,52
More than 800 mutations in diﬀ erent patients are 
entered in the Cambridge database of androgen receptor 
genes as of September, 2011. Most mutations of the 
androgen receptor gene are located within the ligand-
binding domain. The most common functional androgen 
receptor defect results from disruption of the hydro-
phobic ligand-binding pocket, which is necessary for 
repositioning of helix 12 to form the activation function 
2–coregulator interaction surface.
Most mutations of the ligand-binding domain that 
cause complete androgen insensitivity syndrome are 
situated between aminoacid residues 688 and 712, 
739 and 784, and 827 and 870. The ﬁ rst two clusters 
cover most of the ligand-binding pocket. For example, 
a mutation in helix 5 changes the polar bulky arginine 
residue at codon 752 to glutamine (R752Q), resulting in 
loss of hydrogen bonding to the steroid A-ring ketone 
group of an androgen.53 This mutation also results in the 
spontaneous testicular feminisation rat model of 
complete androgen insensitivity syndrome.54
The cluster of mutations between residue 827 and 
870 map to subdomains distant from the ligand-binding 
pocket such as activation function 2, a regulatory surface 
cleft termed binding function 3, and a region that tethers 
the C-terminal tail of the receptor.55,56 The most common 
C-terminal mutation reported in the androgen receptor 
(H917R) is associated with a phenotype of complete 
androgen insensitivity syndrome.57,58
The DNA-binding domain comprises 70 aminoacids 
and is highly conserved within the nuclear receptor 
family. The crystal structure of the domain when bound 
to DNA shows two zinc ﬁ nger modules whose structure 
is dependent on cysteine interaction with the Zn²+ ion 
(ﬁ gure 2). Any mutation of the cysteine residues would 
severely disrupt the zinc ﬁ nger module structure and 
result in complete androgen insensitivity syndrome 
despite androgens binding normally to the ligand-
binding domain.59,60 An α helix in the ﬁ rst zinc module 
(the proximal box) enters the major groove of double-
stranded DNA and forms speciﬁ c basepair contacts that 
are identical for all classical steroid receptors.61 Figure 2 
shows the results of an androgen receptor functional 
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Figure 2: Mutations in the DNA-binding domain ﬁ rst zinc ﬁ nger
The eﬀ ects of substitution of a valine (V) at codon 582 in the DNA-binding domain with phenylalanine (F), glycine 
(G), and leucine (L) are shown in a transactivation assay with the synthetic androgen mibolerone. Responsiveness 
of the reporter gene is related to a complete or partial androgen insensitivity syndrome phenotype. The linear 
stretch of aminoacids comprising the DNA-binding domain is also shown. Mib=mibolerone. CAIS=complete 
androgen insensitivity syndrome. PAIS=partial androgen insensitivity syndrome.
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assay for three diﬀ erent natural mutants when valine is 
replaced at codon 582 in the ﬁ rst zinc module. Trans-
activation of a reporter gene does not occur when valine 
is substituted for phenylalanine, and the pheno type is 
complete androgen insensitivity syndrome. By contrast, 
substitutions with glycine and leucine result in partial 
androgen responsiveness in vitro, which is shown by a 
phenotype of partial androgen insensitivity syndrome. 
The second zinc module includes the distal box, which is 
a receptor dimerisation motif comprising aminoacids 
596–600. The outcome of muta tions in this region of the 
DNA-binding domain is unpredictable. The Cambridge 
database of mutations of the androgen receptor gene 
records an I604S mutation just C terminal to the distal 
box in a pair of twins with complete androgen insen-
sitivity syndrome (un published). A non-conservative 
substitution of the adjacent residue (D605Y) has been 
reported both in patients with partial androgen insen-
sitivity syndrome who were raised male and in those 
with the syndrome who were raised female.62,63
The activation function domain is the largest of the 
three domains, comprises 557 aminoacids, and is the least 
evolutionarily conserved. It has not been crystallised, but 
structure prediction and biochemical analysis suggest a 
disordered domain with intermittent regions of stable 
α-helical structures. Audi and co-workers64 reported the 
only case of a phenotype of complete androgen insen-
sitivity syndrome due to a single mis-sense mutation 
located in the activation function domain. Mis-sense 
mutations that do reside in the activation function domain 
are generally associated with a phenotype of mild 
androgen insensitivity syndrome.65
Management
General management
Management of androgen insensitivity syndrome 
should address functional, sexual, and psychological 
issues such as disclosure, gonadectomy and subsequent 
hormone replacement, creation of a functional vagina, 
and provision of genetic advice. Care needs to be 
individualised, ﬂ exible, and holistic. Management is 
dependent wholly on a multidisciplinary team. Member-
ship of the team varies, but should include key members 
from endocrinology (paediatric or adult), urology, 
gynaecology, and clinical psychology. Additional input 
should be provided as necessary by specialists in neo-
natology, clinical genetics, medical ethics, and social 
services. A multidisciplinary approach is beneﬁ cial in 
terms of both optimum clinical management and 
education of health-care professionals.66–68 Patient advo-
cacy groups (eg, the Androgen Insensitivity Syndrome 
Support Group and dsdFamilies in the UK) should have 
a close supportive role. Support groups related to 
androgen insensitivity syndrome are well represented in 
several countries.
The three categories of androgen insensitivity syn-
drome show phenotypes that can arise from several other 
disorders, particularly with regard to partial disease. 
Many patients were traditionally labelled intersex 
(especially when the external genitalia are ambiguous at 
birth), but those aﬀ ected and their families ﬁ nd the term 
pejorative. Consequently, a new nomenclature and 
classiﬁ cation system has been designed for disorders 
that cause genital abnormalities or a phenotype at 
variance with the genotype. This system is known as the 
Chicago Consensus, which discarded the term intersex 
in favour of the term disorder of sex development.69 
Disorders of sex development are congenital disorders in 
which development of chromosomal, gonadal, or 
anatomical sex is atypical. The classiﬁ cation of causes of 
disorders of sex development is karyotype based and falls 
into three main categories: sex chromosome; 46,XY; 
and 46,XX (panel 2). Confusing terms such as male 
pseudohermaphrodite, female pseudohermaphrodite, 
and true hermaphrodite have been replaced by 46,XY 
disorder of sex development, 46,XX disorder of sex 
development, and ovotesticular disorder of sex develop-
ment, respectively. Thus, complete, partial, and mild 
androgen insensitivity syndromes fall in the generic 
category of 46,XY disorder of sex development and 
represent disorders of androgen action.
These changes in long-standing terminology and 
the subsequent new classiﬁ cation system have been 
universally accepted by health professionals and scientists 
working in the specialty.70–72 A clear and uniform approach 
to the diﬀ erential diagnosis of the causes of disorders of 
sex development is essential for initial management. In 
androgen insensitivity syndrome, management issues 
Panel 2: Classiﬁ cation of causes of disorders of sex 
development
Sex chromosome anomalies
• 45X/46,XY (mixed gonadal dysgenesis)
• 46,XX/46,XY (chimerism)
• 47,XXY (Klinefelter’s syndrome)
46,XX
• Disorder of gonad development—eg, gonadal dysgenesis, 
ovotesticular disorders of sex development
• Fetal androgen excess—eg, congenital adrenal 
hyperplasia, aromatase deﬁ ciency, P450 oxidoreductase 
deﬁ ciency
• Maternal androgen excess—eg, luteoma of pregnancy
46,XY
• Disorder of gonad development—eg, gonadal dysgenesis, 
ovotesticular disorders of sex development
• Disorder of androgen production—eg, mutation of the 
luteinising hormone receptor, 17β-hydroxysteroid 
dehydrogenase deﬁ ciency type 3, 5α-reductase deﬁ ciency 
type 2
• Disorder of androgen action—eg, complete, partial, and 
mild androgen insensitivity syndromes
For more on the Androgen 
Insensitivity Syndrome 
Support Group see http://www.
aissg.org
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vary according to age of presentation and whether the 
phenotype is for complete or partial disease.
Complete androgen insensitivity syndrome
The unexpected ﬁ nding of a gonad during a hernia 
repair in a female infant prompts further investigation.73 
Doctors should take a biopsy of the gonad at the time of 
hernia repair and resite it either subcutaneously or 
within the abdomen pending discussion with the 
parents about the diagnosis and plans for future 
management.10,73 When complete androgen insensitivity 
presents in infancy, early gonadectomy with puberty 
induction later can be done, or gonadectomy can be 
delayed until early adulthood. Parents might choose early 
gonadectomy at a time when their child is unaware of the 
issues surrounding a diagnosis of complete androgen 
insensitivity syndrome. Their decision might be aﬀ ected 
by the risk of gonadal tumour, even though the prevalence 
is very low in childhood.74,75
What are the beneﬁ ts of delaying gonadectomy 
until adolescence or young adulthood? Puberty occurs 
spontaneously within the normal age range for girls. It 
manifests as standard breast development and an 
appropriately timed growth spurt, but is not followed by 
menarche. If gonadectomy is done in childhood, puberty 
should be induced with oestrogen replacement. The 
principles are similar to induction of puberty in girls 
with Turner’s syndrome. Ethinylestradiol is frequently 
used at a starting dose of 2 μg daily from roughly 11 years 
of age. This dose is increased in increments of 2–4 μg 
over about 2 years to reach a daily dose of 30 μg 
(unpublished). Thereafter, and in women who have a 
gonadectomy after puberty, several preparations are 
available, including the natural oestrogen estradiol, 
which can be given orally or transdermally. Synthetic 
oestrogens can be given in the form of the combined oral 
contraceptive pill. Some evidence supports the use of 
natural oestrogens as transdermal hormone replacement 
therapy because this administration method might be 
more physiological than oral delivery.76 However, 
selection of a preparation to suit the individual and 
therefore ensure compliance is probably more important 
than the type and route of administration. Since women 
with complete androgen insensitivity syndrome do not 
have a uterus, they can be treated with continuous, 
unopposed oestrogen. Some women also take supple-
mentary testosterone because they think that it improves 
wellbeing (including libido). These eﬀ ects might be 
oestrogen mediated from aromatisation of testosterone. 
Bone mineral density is reduced in complete androgen 
insensitivity syndrome, in keeping with the ﬁ nding that 
androgens have a direct role in maintenance of bone 
density independent of oestrogens.77 No deﬁ nitive 
evidence shows that bone mineral density is less aﬀ ected 
in women who had late gonadectomies than in women 
who had early gonadectomies, although those who had 
the procedure later in life are substantially taller than 
those who had early gonadectomies.78,79 Women with 
complete androgen insensitivity syndrome do not seem 
to have an increased risk of fractures. Measurement of 
bone density at presentation in the case of young women 
with complete androgen insensitivity syndrome and at 
2 yearly inter vals is a useful index of the eﬀ ectiveness of 
hormone replacement (unpublished).
If gonadectomy was not done in infancy, it is generally 
recommended in early adulthood to avoid the risk of 
gonadal tumours. The procedure is done laparoscopically 
if the gonads are intra-abdominal. Studies have suggested 
an increased tumour risk of greater than 30% in late 
adulthood if gonadectomy is not done,80 and a review81 of 
the risk of adult women with complete androgen 
insensitivity syndrome having a gonadal tumour could 
not be more speciﬁ c than 0–22%. Speciﬁ c analyses in 
large sample groups suggest a germ-cell tumour risk as 
low as 0·8–2%, especially before puberty.74,75 Benign 
tumours of non-germ-cell origin include Sertoli cell 
adenoma and hamartomas.
Germ-cell tumours are classiﬁ ed into ﬁ ve categories on 
the basis of site of presentation, age, histology, and 
chromosomal constitution.82 Tumours associated with 
androgen insensitivity syndrome are in the type 2 
category of seminoma, non-seminoma, and dysger-
minoma. These tumours arise from a premalignant 
precursor called carcinoma in situ or intra-tubular germ-
cell neoplasia, unclassiﬁ ed.83 Carcinoma in situ arises 
A Intratubular germ-cell neoplasia B Gonadoblastoma
C Dysgerminoma D Plap staining of carcinoma in situ
Figure 3: Gonadal tumours in complete androgen insensitivity syndrome
Representative examples of the histology of intratubular germ-cell neoplasia (or carcinoma in situ) (A), 
gonadoblastoma (B), and dysgerminoma (C) in gonads from patients with complete androgen insensitivity 
syndrome, and germ cells indicative of carcinoma in situ stained with placental-like alkaline phosphatase (PLAP; D).
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from gonocytes or primordial germ cells and is thought 
to be the result of a developmental arrest of fetal germ 
cells. It is characterised by an abundance of germ cells 
concentrated in the seminiferous tubules that stain 
positively for tumour markers—eg, placental-like alka-
line phosphatase (ﬁ gure 3), octamer-binding tran-
scription factors 3 and 4, and stem-cell factor.84 Carcinoma 
in situ leads to the development of a gonadoblastoma in 
more than 50% of cases. Some women with complete 
androgen insensitivity syndrome choose not to have a 
gonadectomy despite advice that the tumour risk might 
increase substantially in later adulthood.81 Monitoring is 
based solely on imaging studies because none of the 
tumour markers is detectable in the circulation.
Vaginal surgery is rarely indicated for the creation of a 
functional vagina. Vaginal dilators are an eﬀ ective ﬁ rst-
line treatment;85 some women achieve a similar eﬀ ect 
with sexual intercourse. Adults with complete androgen 
insensitivity syndrome rarely report sexual problems 
(although little evidence exists) once a reasonable vaginal 
length has been achieved. If surgery is needed, it should 
be delayed until consent is given and the woman is able 
to manage dilator therapy herself after surgery.86
Clitoral length and width are shorter in women with 
complete androgen insensitivity syndrome than in those 
without the disorder, presumably because of the absence 
of prenatal and postnatal action of androgens.87,88 Loss of 
fertility is a major issue for many women with complete 
androgen insensitivity syndrome. Individuals can adopt 
or might choose to use donor oocytes and a surrogate 
mother with their partner’s sperm to achieve a pregnancy.
Psychosocial management
Psychosocial support is central to the multidisciplinary 
approach to management of complete androgen insensi-
tivity syndrome.89 Presenting adolescents and parents of 
children with the disorder will have to make important 
decisions at diagnosis about treatments and the timing 
and extent of any surgical interventions. Concerns 
should focus on assimilation of the disconnect between 
chromosomal, gonadal, and phenotypic sex and its 
implications. Most centres caring for patients with 
disorders of sex development provide specialist psycho-
logical support.70
Historically, a paternalistic view about disclosure 
prevailed in disorders such as complete androgen 
insensitivity syndrome to protect families from shock 
and despair.5,90 This approach has largely been abandoned 
in favour of partial or full disclosure.91,92 One study93 that 
explored the emotional reactions of parents and adult 
patients to clinical diagnosis of androgen insensitivity 
syndrome showed a range of responses including shock, 
grief, and anger in both mothers and adult patients. An 
investigation94 of disorders of sex development in which 
adults with complete androgen insensitivity syndrome 
formed the largest diagnostic group, showed that 
younger women with the syndrome were better informed 
than were older women with the syndrome; many had 
full disclosure by 15 years of age. Many patients wished 
that they had been informed sooner than they had been 
about aspects of diagnosis, such as the presence of testes 
and the nature of the karyotype.
Disclosure must be done carefully, especially for 
children with complete androgen insensitivity syndrome 
as they approach pubertal age. Issues to address include 
implications of an XY karyotype, the presence of testes, 
absence of a uterus, infertility, and sexual function. Such 
information should be shared with parents initially, with 
age-appropriate disclosure as the child grows up.95 
Mothers of girls with complete androgen insensitivity 
syndrome might feel a sense of guilt for having passed 
on the disorder and fear rejection after the facts are 
disclosed (unpublished). A heuristic approach to the 
ideas and components of sex development is a useful 
principle to adopt to understand physical and psycho-
logical sex-related development.
Long-term psychosexual outcome in complete andro-
gen insensitivity syndrome suggests a trajectory of 
female-typical development, with the assimilation of a 
female identity and female-typical behaviour, and 
psychological wellbeing similar to that of other women.96,97 
Less positive outcomes have been reported for sexual 
functioning and sexual quality of life.98 Problems with 
desire, arousal, and dyspareunia were signiﬁ cant in a 
group of women with XY disorders of sex development, 
most of which were due to complete androgen insen-
sitivity syndrome.99 Altered gender-related self-concept 
can be problematic, but might respond to psychological 
intervention. Diﬃ  culties with vaginal penetration can 
occur, but for many women with complete androgen 
insensitivity syndrome, the use of vaginal dilators and 
regular penetrative intercourse might correct the eﬀ ects 
of vaginal hypoplasia.
Partial androgen insensitivity syndrome
Since the phenotype of partial androgen insensitivity 
syndrome generally presents as ambiguous genitalia in 
neonates, establishment of a diagnosis and reaching a 
decision on sex assignment and early management 
issues that need to be addressed are key. The phenotype 
of partial androgen insensitivity syndrome can result 
from several causes of XY disorders of sex development; 
thus deﬁ nitive diagnosis relies on identiﬁ cation of a 
mutation in the androgen receptor gene that results 
in abnormal receptor function. Such information is 
seldom available before sex assignment. A short course 
of testosterone (25 mg intramuscularly monthly for 
3 months) or topical dihydrotestosterone gel can be 
useful to determine androgen responsiveness.99
Most infants with partial androgen insensitivity 
syndrome are raised male. Little information is available 
about outcome at puberty. However, an external mascu-
linisation score devised to quantify the degree of under-
masculinisation in neonates with XY disorders of sex 
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development100 might be a reasonable predictor of viril-
isation at puberty in infants with partial androgen 
insensitivity syndrome who were assigned male 
(un pub lished). Androgen supplementation might be 
needed at puberty in patients with androgen resistance, 
but is not alway necessary. Surgery is done during the 
second to third year of life to repair hypospadias and bring 
undescended testes into the scrotum. Gynaecomastia 
often occurs in adolescence, and requires reduction 
mammoplasty. Breast cancer can occur rarely in men with 
partial androgen insensitivity syndrome.101 By contrast, 
apart from a case report of a juvenile ﬁ broadenoma of the 
breast in a young woman,102 no reports seem to exist of 
breast cancer in women with complete androgen 
insensitivity syndrome.
An infant with partial androgen insensitivity syndrome 
who is assigned female will need a genitoplasty pro-
cedure and gonadectomy before puberty to avoid the risk 
of virilisation. Oestrogen replacement is needed to 
induce female puberty. The risk of germ-cell tumours is 
higher in partial than in complete androgen insensitivity 
syndrome, with a suggested incidence of 15% and even 
higher if the testes are not scrotal in position.103 
Psychological distress is more common in adults with 
partial androgen insensitivity syndrome than in those 
with complete androgen insensitivity syndrome, irres-
pective of whether they were raised male or female. In 
one study of men with partial androgen insensitivity 
syndrome, all aspects of sexual activity were substantially 
impaired.104 However, outcome studies are few and 
comprise small numbers. Studies with large sample 
sizes that use standardised and validated measures of 
sexual function are needed. Even less information is 
available in patients with mild androgen insensitivity 
syndrome, but individuals might need reduction 
mammoplasty for gynaecomastia and supplemental 
androgens to treat oligospermia.
To improve diagnosis and management of all 
causes of XY disorders of sex development (including 
complete and particularly partial androgen insensitivity 
syndromes), multicentre collaboration at national and 
international levels is needed. The EuroDSD consortium, 
which has a register of more than 1000 cases, is a 
promising start, and has evolved internationally to 
become the I-DSD registry. Almost a third of the cases on 
the European register are associated with disorders of 
androgen action.
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